AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8993761 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of anti-herpes dialysate (AH-DLE)
Number of subjects: 37
Study 8993761 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of anti-herpes dialysate (AH-DLE)
Number of subjects: 37
Study 8993761 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of anti-herpes dialysate (AH-DLE)
Number of subjects: 37
Study 1476047 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg exclusion diet
Number of subjects: 0
Study 6379630 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aqueous nasal spray (100 micrograms into each nostril twice daily)
Number of subjects: 40
Study 6379630 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate pressurized nasal spray (100 micrograms into each nostril twice daily)
Number of subjects: 40
Study 30764814 — intervention group
Group type: EXPERIMENTAL
Intervention: Online teaching on suicide prevention via brief online videos plus two standardized patient (SP) interactions (face-to-face and telehealth)
Number of subjects: 0
Study 30764814 — intervention group
Group type: COMPARATOR
Intervention: Online teaching on suicide prevention via brief online videos
Number of subjects: 0
Study 30396620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise for 8 weeks
Number of subjects: 132
Study 30396620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Tai Chi)
Number of subjects: 132
Study 26938814 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone/amiloride (12.5/2.5 mg)
Number of subjects: 655
Study 26938814 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 655
Study 25442824 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial shrinkage of blastocoele using laser pulse
Number of subjects: 185
Study 21902621 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) 75 mg qd then 25 mg qd
Number of subjects: 368
Study 21902621 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) 600 mg qd
Number of subjects: 368
Study 21902621 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV)
Number of subjects: 368
Study 21902621 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 368
Study 20935517 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent A (H1N1) pandemic vaccine (Panenza®)
Number of subjects: 0
Study 20935517 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent split inactivated vaccine (Vaxigrip®)
Number of subjects: 0
Study 18595959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide (32 microg per nostril at bedtime)
Number of subjects: 62
Study 18595959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 16208072 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug misuse and abuse prevention program (1 hour, once a week for 5 weeks)
Number of subjects: 49
Study 16208072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 49
Study 12587769 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 100
Study 12587769 — intervention group
Group type: COMPARATOR
Intervention: Panadeine
Number of subjects: 100
Study 12587769 — intervention group
Group type: COMPARATOR
Intervention: Etodolac
Number of subjects: 100
Study 12587769 — intervention group
Group type: COMPARATOR
Intervention: All three drugs
Number of subjects: 100
Study 10999082 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Drug Monotherapy (SDM)
Number of subjects: 70
Study 10999082 — intervention group
Group type: COMPARATOR
Intervention: Step Care Therapy (SCT)
Number of subjects: 70
Study 8527293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose (various doses)
Number of subjects: 20
Study 8527293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (empty dose)
Number of subjects: 20
Study 2255839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 50 mcg/kg
Number of subjects: 40
Study 2255839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 mcg/kg
Number of subjects: 40
Study 2255839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 150 mcg/kg
Number of subjects: 40
Study 2255839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 200 mcg/kg
Number of subjects: 40
Study 2255839 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treated carriers)
Number of subjects: 40
Study 7237448 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol (EE2)
Number of subjects: 63
Study 7237448 — intervention group
Group type: COMPARATOR
Intervention: tamoxifen
Number of subjects: 63
Study 31893396 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-cuff-release technique (220 mmHg for 3 min)
Number of subjects: 10
Study 31893396 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive hypoxia (FiO2 at 21%, 18%, 15%, and 12%)
Number of subjects: 10
Study 31893396 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-cuff-release technique (220 mmHg for 3 min) during progressive hypoxia
Number of subjects: 10
Study 30760256 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan's Mobilisation With Movement (MWM)
Number of subjects: 0
Study 30760256 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (detuned laser)
Number of subjects: 0
Study 28098838 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (oral doses)
Number of subjects: 33
Study 26485380 — intervention group
Group type: EXPERIMENTAL
Intervention: Active occlusal interference (AI)
Number of subjects: 7
Study 26485380 — intervention group
Group type: COMPARATOR
Intervention: Dummy interference (DI)
Number of subjects: 7
Study 23504490 — intervention group
Group type: EXPERIMENTAL
Intervention: Fanning technique
Number of subjects: 54
Study 23504490 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 54
Study 21873912 — intervention group
Group type: EXPERIMENTAL
Intervention: DigniCare Stool Management System (device A)
Number of subjects: 10
Study 21873912 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexi-Seal Fecal Management System (device B)
Number of subjects: 10
Study 21873912 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiFlo Indwelling Bowel Catheter System (device C)
Number of subjects: 10
Study 19479385 — intervention group
Group type: EXPERIMENTAL
Intervention: Satranidazole mucoadhesive gel (SC30 formulation)
Number of subjects: 0
Study 19479385 — intervention group
Group type: COMPARATOR
Intervention: Marketed metronidazole gel (Metrogyl gel)
Number of subjects: 0
Study 17589294 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified HLA‐A2‐binding gp100(209‐2M) peptide vaccination
Number of subjects: 0
Study 15519186 — intervention group
Group type: EXPERIMENTAL
Intervention: HAES‐steril 6% (HES 200/0.5)
Number of subjects: 20
Study 15519186 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluven 6% (HES 130/0.4)
Number of subjects: 20
Study 15519186 — intervention group
Group type: COMPARATOR
Intervention: Control (Ringer's lactate group)
Number of subjects: 20
Study 11527062 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom acupuncture
Number of subjects: 0
Study 11527062 — intervention group
Group type: COMPARATOR
Intervention: Traditional needle acupuncture
Number of subjects: 0
Study 9753216 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic hypothermia
Number of subjects: 131
Study 9753216 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Number of subjects: 131
Study 7836706 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding episodes
Number of subjects: 94
Study 7836706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of bleeding
Number of subjects: 94
Study 7836706 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebleeding episodes
Number of subjects: 94
Study 7836706 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous rebleedings and time since first bleeding
Number of subjects: 94
Study 3221374 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10-20 mg per day
Number of subjects: 0
Study 3221374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 160 mg per day
Number of subjects: 0
Study 3221374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 75-300 micrograms per day
Number of subjects: 0
Study 30231990 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (LDRT) - 6 × 1 Gy in 2 weeks
Number of subjects: 56
Study 30231990 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment - 6 × 0 Gy in 2 weeks
Number of subjects: 56
Study 30231990 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and functioning measured by AUSCAN
Number of subjects: 56
Study 30231990 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measured by SF36
Number of subjects: 56
Study 30231990 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory outcomes (erythrocyte sedimentation rate, C-reactive protein serum levels, effusion, synovial thickening, power Doppler signal on ultrasound)
Number of subjects: 56
Study 26418670 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin treatment for 12 weeks (Finnish patients)
Number of subjects: 372
Study 26418670 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin treatment for 12-16 weeks (Swedish patients)
Number of subjects: 372
Study 25338961 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5%) with epinephrine (1:200,000) as supplemental anesthesia at the end of surgery
Number of subjects: 40
Study 25338961 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) as supplemental anesthesia at the end of surgery
Number of subjects: 40
Study 22552838 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Exercise Lifestyle Program (HEELP)
Number of subjects: 148
Study 22552838 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148
Study 20534751 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (4 weeks)
Number of subjects: 44
Study 20534751 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (20 weeks)
Number of subjects: 44
Study 20534751 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 19034033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol administered orally for a week before and after surgery (n = 25)
Number of subjects: 50
Study 19034033 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n = 25)
Number of subjects: 50
Study 17803434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost 0.005%
Number of subjects: 49
Study 17803434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0025%
Number of subjects: 49
Study 17803434 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 49
Study 17803434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 15328547 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 32
Study 15328547 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 32
Study 10867155 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT+3TC
Number of subjects: 19
Study 10867155 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT+ddI
Number of subjects: 19
Study 9101195 — intervention group
Group type: EXPERIMENTAL
Intervention: Second trabeculectomy with mitomycin-C (MMC)
Number of subjects: 46
Study 9101195 — intervention group
Group type: COMPARATOR
Intervention: Second trabeculectomy without mitomycin-C (MMC)
Number of subjects: 46
Study 8403177 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg sublingual triazolam
Number of subjects: 100
Study 8403177 — intervention group
Group type: COMPARATOR
Intervention: 10 mg oral diazepam
Number of subjects: 100
Study 3709641 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of PY 108‐068
Number of subjects: 6
Study 3709641 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of PY 108‐068
Number of subjects: 6
Study 3709641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29055031 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-neutral vaccination with AS04-adjuvanted HPV16/18 vaccine (Arm A)
Number of subjects: 39420
Study 29055031 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination of girls and hepatitis B-virus (HBV) vaccination of boys (Arm B)
Number of subjects: 39420
Study 29055031 — intervention group
Group type: COMPARATOR
Intervention: Gender-neutral HBV vaccination (Arm C)
Number of subjects: 39420
Study 27536947 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 70
Study 27536947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27536947 — intervention group
Group type: COMPARATOR
Intervention: Rituximab and Placebo
Number of subjects: 70
Study 25468084 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet reconstruction techniques including leaflet plication, nodular unfolding, double pericardial patching, complete pericardial leaflet replacement, leaflet extension, Gore‐Tex reinforcement
Number of subjects: 65
Study 25468084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gore‐Tex reinforcement and leaflet extension
Number of subjects: 65
Study 25468084 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pericardial leaflet replacements and double pericardial reconstructions
Number of subjects: 65
Study 25468084 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval valve replacement
Number of subjects: 65
Study 21798721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/d) plus mood stabilizer (lithium or valproate)
Number of subjects: 584
Study 21798721 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus mood stabilizer (lithium or valproate)
Number of subjects: 584
Study 20437789 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circulation (MECC)
Number of subjects: 40
Study 20437789 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass (CCPB)
Number of subjects: 40
Study 18682411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O)‐based anaesthesia
Number of subjects: 2050
Study 18682411 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (N2O)‐free anaesthesia
Number of subjects: 2050
Study 15996411 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol (POL)
Number of subjects: 20
Study 15996411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate (STS)
Number of subjects: 20
Study 15996411 — intervention group
Group type: COMPARATOR
Intervention: Polidocanol (POL) and Sodium tetradecyl sulfate (STS)
Number of subjects: 20
Study 12858461 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES plus education
Number of subjects: 34
Study 12858461 — intervention group
Group type: COMPARATOR
Intervention: Education only (EDU)
Number of subjects: 34
Study 12858461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 10551071 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried bone allografts (DFDBA)
Number of subjects: 24
Study 10551071 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized natural bovine bone mineral xenograft (DBBMX)
Number of subjects: 24
Study 8677906 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 1.5 g/m2 and mesna at 30% of the ifosfamide dose, administered i.v. daily for 5 days every 21 days.
Number of subjects: 38
Study 1815962 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 8
Study 1815962 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (after oral pretreatment)
Number of subjects: 8
Study 1815962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1815962 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 8
Study 6824300 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine (3.5 ml)
Number of subjects: 340
Study 6824300 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine (3 ml)
Number of subjects: 340
Study 31271569 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A 0.05% (twice a day for 10 days before and 10 days after surgery)
Number of subjects: 76
Study 31271569 — intervention group
Group type: COMPARATOR
Intervention: Control group (31 patients who did not receive cyclosporine treatment)
Number of subjects: 76
Study 29464877 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation program
Number of subjects: 1200
Study 29464877 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1200
Study 27155962 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Socks with Textured Insoles (CSTI)
Number of subjects: 12
Study 27155962 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Socks with Smooth Insoles (CSSI)
Number of subjects: 12
Study 27155962 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth Socks with Textured Insoles (SSTI)
Number of subjects: 12
Study 27155962 — intervention group
Group type: COMPARATOR
Intervention: Smooth Socks with Smooth Insoles (SSSI)
Number of subjects: 12
Study 25410066 — intervention group
Group type: EXPERIMENTAL
Intervention: Horsetail mixture
Number of subjects: 60
Study 25410066 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control was)
Number of subjects: 60
Study 21982875 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous aerobic exercise for 1 year
Number of subjects: 100
Study 21982875 — intervention group
Group type: COMPARATOR
Intervention: Usual inactivity
Number of subjects: 100
Study 20848900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranquilization Needling (TN)
Number of subjects: 60
Study 20848900 — intervention group
Group type: COMPARATOR
Intervention: Eight Confluence Acupoints (ECA)
Number of subjects: 60
Study 17641562 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese acupuncture
Number of subjects: 7
Study 17641562 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine acupuncture
Number of subjects: 7
Study 17641562 — intervention group
Group type: COMPARATOR
Intervention: Both acupuncture styles
Number of subjects: 7
Study 17641562 — intervention group
Group type: COMPARATOR
Intervention: Neither group
Number of subjects: 7
Study 15731510 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed learning
Number of subjects: 0
Study 15731510 — intervention group
Group type: COMPARATOR
Intervention: Self-directed learning
Number of subjects: 0
Study 12205259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen 15 mg/kg (Group A)
Number of subjects: 70
Study 12205259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen 30 mg/kg (Group B)
Number of subjects: 70
Study 12205259 — intervention group
Group type: COMPARATOR
Intervention: Oral acetaminophen 15 mg/kg (Group C)
Number of subjects: 70
Study 12205259 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scores for satisfaction of parents
Number of subjects: 70
Study 9809555 — intervention group
Group type: EXPERIMENTAL
Intervention: T-20 (100 mg twice daily)
Number of subjects: 16
Study 9809555 — intervention group
Group type: EXPERIMENTAL
Intervention: T-20 (various doses)
Number of subjects: 16
Study 7665721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg
Number of subjects: 278
Study 7665721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 16 mg
Number of subjects: 278
Study 7665721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 32 mg
Number of subjects: 278
Study 7665721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 278
Study 7665721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 2819565 — intervention group
Group type: EXPERIMENTAL
Intervention: Water added to incubators
Number of subjects: 180
Study 2819565 — intervention group
Group type: COMPARATOR
Intervention: No water added to incubators (control)
Number of subjects: 180
Study 173048 — intervention group
Group type: EXPERIMENTAL
Intervention: Eladent cleaner
Number of subjects: 0
Study 173048 — intervention group
Group type: EXPERIMENTAL
Intervention: Kukident cleaner
Number of subjects: 0
Study 173048 — intervention group
Group type: EXPERIMENTAL
Intervention: Steradent cleaner
Number of subjects: 0
Study 29877778 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Self-Management (PSM) group
Number of subjects: 87
Study 29877778 — intervention group
Group type: COMPARATOR
Intervention: Patient Self-Testing (PST) group
Number of subjects: 87
Study 28587629 — intervention group
Group type: EXPERIMENTAL
Intervention: USMART program
Number of subjects: 50
Study 28587629 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 25369608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (mean dose 7-9 g)
Number of subjects: 61
Study 25369608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 23100042 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 5
Study 23100042 — intervention group
Group type: COMPARATOR
Intervention: PCV
Number of subjects: 5
Study 21790518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Number of subjects: 60
Study 21790518 — intervention group
Group type: COMPARATOR
Intervention: Dorsal penile nerve block
Number of subjects: 60
Study 19432498 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan/amlodipine 40/5 mg
Number of subjects: 692
Study 19432498 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan/amlodipine 40/10 mg
Number of subjects: 692
Study 19432498 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan/amlodipine/HCTZ 40/10/12.5 mg
Number of subjects: 692
Study 19432498 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan/amlodipine (+/− HCTZ)
Number of subjects: 692
Study 17061974 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the early fertile time from the fertility monitor (first rise in E3G until LH surge)
Number of subjects: 1453
Study 17061974 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the late fertile time from the fertility monitor (onset of LH surge and following 2 days)
Number of subjects: 1453